Редактирование: FAAH

Fatty-acid amide hydrolase 1 (EC 3.5.1.99) (Anandamide amidohydrolase 1) (Fatty acid ester hydrolase) (EC 3.1.1.-) (Oleamide hydrolase 1) [FAAH1]

==Publications==

{{medline-entry
|title=Endocannabinoid genetic variation enhances vulnerability to THC reward in adolescent female mice.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/32095523
|abstract=Adolescence represents a developmental period with the highest risk for initiating cannabis use. Little is known about whether genetic variation in the endocannabinoid system alters mesolimbic reward circuitry to produce vulnerability to the rewarding properties of the exogenous cannabinoid Δ -tetrahydrocannabinol (THC). Using a genetic knock-in mouse model ([[FAAH]] ) that biologically recapitulates the human polymorphism associated with problematic drug use, we find that in adolescent female mice, but not male mice, this [[FAAH]] polymorphism enhances the mesolimbic dopamine circuitry projecting from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) and alters cannabinoid receptor 1 (CB R) levels at inhibitory and excitatory terminals in the VTA. These developmental changes collectively increase vulnerability of adolescent female [[FAAH]]  mice to THC preference that persists into adulthood. Together, these findings suggest that this endocannabinoid genetic variant is a contributing factor for increased susceptibility to cannabis dependence in adolescent females.
|mesh-terms=* Aging
* Amidohydrolases
* Animals
* Axons
* Choice Behavior
* Dronabinol
* Endocannabinoids
* Female
* Genetic Variation
* Male
* Mice, Inbred C57BL
* Nerve Net
* Nucleus Accumbens
* Polymorphism, Single Nucleotide
* Receptor, Cannabinoid, CB1
* Reward
* Tyrosine 3-Monooxygenase
* Ventral Tegmental Area

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015690
}}
{{medline-entry
|title=Pharmacological convergence reveals a lipid pathway that regulates C. elegans lifespan.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/30911178
|abstract=Phenotypic screening has identified small-molecule modulators of aging, but the mechanism of compound action often remains opaque due to the complexities of mapping protein targets in whole organisms. Here, we combine a library of covalent inhibitors with activity-based protein profiling to coordinately discover bioactive compounds and protein targets that extend lifespan in Caenorhabditis elegans. We identify JZL184-an inhibitor of the mammalian endocannabinoid (eCB) hydrolase monoacylglycerol lipase (MAGL or MGLL)-as a potent inducer of longevity, a result that was initially perplexing as C. elegans does not possess an MAGL ortholog. We instead identify [[FAAH]]-4 as a principal target of JZL184 and show that this enzyme, despite lacking homology with MAGL, performs the equivalent metabolic function of degrading eCB-related monoacylglycerides in C. elegans. Small-molecule phenotypic screening thus illuminates pure pharmacological connections marking convergent metabolic functions in distantly related organisms, implicating the [[FAAH]]-4/monoacylglyceride pathway as a regulator of lifespan in C. elegans.
|mesh-terms=* Animals
* Benzodioxoles
* Caenorhabditis elegans
* Endocannabinoids
* Enzyme Inhibitors
* Longevity
* Molecular Structure
* Monoacylglycerol Lipases
* Piperidines

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548519
}}
{{medline-entry
|title=Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26976670
|abstract=Cannabinoid CB2 receptors (CB2Rs) are emerging as important therapeutic targets in brain disorders that typically involve neurometabolic alterations. We here addressed the possible role of CB2Rs in the regulation of glucose uptake in the mouse brain. To that aim, we have undertaken 1) measurement of (3)H-deoxyglucose uptake in cultured cortical astrocytes and neurons and in acute hippocampal slices; 2) real-time visualization of fluorescently labeled deoxyglucose uptake in superfused hippocampal slices; and 3) in vivo PET imaging of cerebral (18)F-fluorodeoxyglucose uptake. We now show that both selective (JWH133 and GP1a) as well as non-selective (WIN55212-2) CB2R agonists, but not the CB1R-selective agonist, ACEA, stimulate glucose uptake, in a manner that is sensitive to the CB2R-selective antagonist, AM630. Glucose uptake is stimulated in astrocytes and neurons in culture, in acute hippocampal slices, in different brain areas of young adult male C57Bl/6j and CD-1 mice, as well as in middle-aged C57Bl/6j mice. Among the endocannabinoid metabolizing enzymes, the selective inhibition of COX-2, rather than that of [[FAAH]], MAGL or α,βDH6/12, also stimulates the uptake of glucose in hippocampal slices of middle-aged mice, an effect that was again prevented by AM630. However, we found the levels of the endocannabinoid, anandamide reduced in the hippocampus of TgAPP-2576 mice (a model of β-amyloidosis), and likely as a consequence, COX-2 inhibition failed to stimulate glucose uptake in these mice. Together, these results reveal a novel general glucoregulatory role for CB2Rs in the brain, raising therapeutic interest in CB2R agonists as nootropic agents.
|mesh-terms=* Aging
* Alzheimer Disease
* Amyloid beta-Protein Precursor
* Amyloidosis
* Animals
* Arachidonic Acids
* Astrocytes
* Brain
* Cannabinoid Receptor Modulators
* Cells, Cultured
* Cyclooxygenase 2
* Cyclooxygenase 2 Inhibitors
* Endocannabinoids
* Glucose
* Hydroxyethylrutoside
* Male
* Mice, Inbred C57BL
* Mice, Transgenic
* Neurons
* Nootropic Agents
* Polyunsaturated Alkamides
* Receptor, Cannabinoid, CB2
* Tissue Culture Techniques
|keywords=* 10252734)
* 108223)
* 11507802)
* 2-Arachidonoylglycerol (PubChem CID
* 2-Deoxy-d-glucose (PubChem CID
* 25021165)
* 3177)
* 4302963)
* 439501)
* 5281969)
* 5282280)
* 5311006)
* 5311501)
* 6918505)
* AM630 (PubChem CID
* Anandamide (AEA)
* Anandamide (PubChem CID
* Arachidonyl-2-chloroethylamide (PubChem CID
* Cannabinoid CB(2) receptor
* Cerebral glucose uptake
* Cyclooxygenase-2 (COX-2)
* DuP697 (PubChem CID
* GP1a (PubChem CID
* JWH133 (PubChem CID
* JZL184 (PubChem CID
* LY2183240 (PubChem CID
* Ouabain (PubChem CID
* Positron emission tomography (PET)
* WIN55212-2 (PubChem CID
* WWL70 (PubChem CID:17759121)
* β-amyloid
|full-text-url=https://sci-hub.do/10.1016/j.neuropharm.2016.03.015
}}
{{medline-entry
|title=Sustained Endocannabinoid Signaling Compromises Decidual Function and Promotes Inflammation-induced Preterm Birth.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26900150
|abstract=Recent studies provide evidence that premature maternal decidual senescence resulting from heightened mTORC1 signaling is a cause of preterm birth (PTB). We show here that mice devoid of fatty acid amide hydrolase ([[FAAH]]) with elevated levels ofN-arachidonyl ethanolamide (anandamide), a major endocannabinoid lipid mediator, were more susceptible to PTB upon lipopolysaccharide (LPS) challenge. Anandamide is degraded by [[FAAH]] and primarily works by activating two G-protein-coupled receptors CB1 and CB2, encoded by Cnr1 and Cnr2, respectively. We found thatFaah(-/-)decidual cells progressively underwent premature senescence as marked by increased senescence-associated β-galactosidase (SA-β-Gal) staining and γH2AX-positive decidual cells. Interestingly, increased endocannabinoid signaling activated MAPK p38, but not p42/44 or mTORC1 signaling, inFaah(-/-)deciduae, and inhibition of p38 halted premature decidual senescence. We further showed that treatment of a long-acting anandamide in wild-type mice at midgestation triggered premature decidual senescence utilizing CB1, since administration of a CB1 antagonist greatly reduced the rate of PTB inFaah(-/-)females exposed to LPS. These results provide evidence that endocannabinoid signaling is critical in regulating decidual senescence and parturition timing. This study identifies a previously unidentified pathway in decidual senescence, which is independent of mTORC1 signaling. 
|mesh-terms=* Amidohydrolases
* Animals
* Arachidonic Acids
* Cells, Cultured
* Decidua
* Endocannabinoids
* Female
* Gene Deletion
* Inflammation
* Lipopolysaccharides
* MAP Kinase Signaling System
* Male
* Mice
* Polyunsaturated Alkamides
* Premature Birth
* Signal Transduction
|keywords=* anandamide (N-arachidonoylethanolamine) (AEA)
* cannabinoid receptor type 1 (CB1)
* fatty acid metabolism
* pregnancy
* senescence
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825023
}}
{{medline-entry
|title=Decreased anxiety in juvenile rats following exposure to low levels of chlorpyrifos during development.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26642910
|abstract=Exposure to chlorpyrifos (CPF) during the late preweanling period in rats inhibits the endocannabinoid metabolizing enzymes fatty acid hydrolase ([[FAAH]]) and monoacylglycerol lipase (MAGL), resulting in accumulation of their respective substrates anandamide (AEA) and 2-arachidonylglycerol (2-AG). This occurs at 1.0mg/kg, but at a lower dosage (0.5mg/kg) only [[FAAH]] and AEA are affected with no measurable inhibition of either cholinesterase (ChE) or MAGL. The endocannabinoid system plays a vital role in nervous system development and may be an important developmental target for CPF. The endocannabinoid system plays an important role in the regulation of anxiety and, at higher dosages, developmental exposure to CPF alters anxiety-like behavior. However, it is not clear whether exposure to low dosages of CPF that do not inhibit ChE will cause any persistent effects on anxiety-like behavior. To determine if this occurs, 10-day old rat pups were exposed daily for 7 days to either corn oil or 0.5, 0.75, or 1.0mg/kg CPF by oral gavage. At 12h following the last CPF administration, 1.0mg/kg resulted in significant inhibition of [[FAAH]], MAGL, and ChE, whereas 0.5 and 0.75mg/kg resulted in significant inhibition of only [[FAAH]]. AEA levels were significantly elevated in all three treatment groups as were palmitoylethanolamide and oleoylethanolamide, which are also substrates for [[FAAH]]. 2-AG levels were significantly elevated by 0.75 and 1.0mg/kg but not 0.5mg/kg. On day 25, the latency to emerge from a dark container into a highly illuminated novel open field was measured as an indicator of anxiety. All three CPF treatment groups spent significantly less time in the dark container prior to emerging as compared to the control group, suggesting a decreased level of anxiety. This demonstrates that repeated preweanling exposure to dosages of CPF that do not inhibit brain ChE can induce a decline in the level of anxiety that is detectable during the early postweanling period.
|mesh-terms=* Aging
* Analysis of Variance
* Animals
* Animals, Newborn
* Anxiety
* Arachidonic Acids
* Chlorpyrifos
* Cholinesterase Inhibitors
* Cholinesterases
* Cohort Studies
* Disease Models, Animal
* Endocannabinoids
* Female
* Male
* Oleic Acids
* Polyunsaturated Alkamides
* Rats
* Rats, Sprague-Dawley
* Sex Factors
|keywords=* Anxiety
* Chlorpyrifos
* Developmental
* Endocannabinoid
* Organophosphate insecticides
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580823
}}
{{medline-entry
|title=Enhanced microglial activity in [[FAAH]](-/-) animals.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/25534441
|abstract=Several lines of evidence suggest that the endocannabinoid system is involved in the regulation of glial activity. Enhanced levels of the endocannabinoid N-arachidonoyl ethanolamine (AEA, also referred to as anandamide) as well as non-cannabinoid lipids like palmitoylethanolamine (PEA) due to genetic deletion or pharmacologic blockade of its degrading enzyme fatty acid amide hydrolase ([[FAAH]]) reduced neuroinflammatory changes in models of neurodegeneration. Now we addressed the question if genetic deletion of [[FAAH]] also influences age-related neuroinflammation. To answer this question we compared the number and size of microglia in young and old wild-type and [[FAAH]](-/-) mice and analysed the distribution of microglia sizes in the four groups. Additionally, we analysed IL-6 and IL-1β levels with ELISA and astrocyte activities as ratio of GFAP-positive areas in the hippocampus. Ageing was associated with an increased number and activity of microglia, elevated IL-6 and IL-1β levels and enhanced area covered by astrocytes in wild-type animals. Unexpectedly, in [[FAAH]](-/-) animals the number of microglia and the ratio of activated microglia and IL-1β level were already higher in young animals than in age-matched wild-type controls. There was no further age-related increase in these inflammation markers in the knockout line. Our results suggest that AEA is involved in the regulation of microglia activity. Life-long elevation of AEA levels disturbs microglial regulation and leads to pro-inflammatory changes.
|mesh-terms=* Aging
* Amidohydrolases
* Animals
* Astrocytes
* Cell Size
* Cytokines
* Genotype
* Glial Fibrillary Acidic Protein
* Hippocampus
* Inflammation
* Mice
* Mice, Inbred C57BL
* Mice, Knockout
* Microglia
|keywords=* Ageing
* Anandamide
* Astrocyte
* FAAH
* Microglia
* Neuroinflammation
|full-text-url=https://sci-hub.do/10.1016/j.lfs.2014.12.016
}}
{{medline-entry
|title=Normal aging in rats and pathological aging in human Alzheimer's disease decrease [[FAAH]] activity: modulation by cannabinoid agonists.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/25456842
|abstract=Anandamide is an endocannabinoid involved in several physiological functions including neuroprotection. Anandamide is synthesized on demand and its endogenous level is regulated through its degradation, where fatty acid amide hydrolase plays a major role. The aim of this study was to characterize anandamide breakdown in physiological and pathological aging and its regulation by CB1 and CB2 receptor agonists. Fatty acid amide hydrolase activity was analyzed in an independent cohort of human cortical membrane samples from control and Alzheimer's disease patients, and in membrane and synaptosomes from adult and aged rat cerebral cortex. Our results demonstrate that fatty acid amide hydrolase activity decreases in the frontal cortex from human patients with Alzheimer's disease and this effect is mimicked by Aβ(1-40) peptide. This activity increases and decreases in aged rat cerebrocortical membranes and synaptosomes, respectively. Also, while the presence of JWH-133, a CB2 selective agonist, slightly increases anandamide hydrolysis in human controls, it decreases this activity in adults and aged rat cerebrocortical membranes and synaptosomes. In the presence of WIN55,212-2, a mixed CB1/CB2 agonist, anandamide hydrolysis increases in Alzheimer's disease patients but decreases in human controls as well as in adult and aged rat cerebrocortical membranes and synaptosomes. Although a similar profile is observed in fatty acid amide hydrolase activity between aged rat synaptic endings and human Alzheimer's disease brains, it is differently modulated by CB1/CB2 agonists. This modulation leads to a reduced availability of anandamide in Alzheimer's disease and to an increased availability of this endocannabinoid in aging.
|mesh-terms=* Aged
* Aged, 80 and over
* Aging
* Alzheimer Disease
* Amidohydrolases
* Amyloid beta-Peptides
* Animals
* Arachidonic Acids
* Benzamides
* Benzoxazines
* Cannabinoid Receptor Agonists
* Cannabinoids
* Carbamates
* Case-Control Studies
* Cerebral Cortex
* Endocannabinoids
* Enzyme Inhibitors
* Female
* Frontal Lobe
* Humans
* In Vitro Techniques
* Male
* Middle Aged
* Morpholines
* Naphthalenes
* Polyunsaturated Alkamides
* Rats
* Rats, Wistar
* Synaptosomes
|keywords=* Aging
* Alzheimer's disease
* Anandamide
* Cannabinoid receptors
* Central nervous system
* Fatty acid amide hydrolase
|full-text-url=https://sci-hub.do/10.1016/j.exger.2014.10.011
}}
{{medline-entry
|title=Induction of endocannabinoid levels in juvenile rat brain following developmental chlorpyrifos exposure.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/23761300
|abstract=The endogenous cannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (AEA) play vital roles during nervous system development. The degradation of 2-AG and AEA is mediated by monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase ([[FAAH]]), respectively. These enzymes are inhibited following developmental chlorpyrifos (CPF) exposure. To investigate whether this inhibition is persistent or whether accumulation of endocannabinoids in the brain occurs, 10-day-old rat pups were orally exposed daily for 7 days to either corn oil or increasing dosages of CPF (1, 2.5, or 5mg/kg), and forebrains were collected at 4, 12, 24, and 48h following the last administration. All dosages inhibited cholinesterase (ChE), [[FAAH]], and MAGL, and elevated AEA and 2-AG levels with the greatest effect occurring at 12h with ChE, [[FAAH]], AEA, and 2-AG and at 4h with MAGL. With the high dosage, return to control levels occurred with 2-AG (48h) only. With the medium dosage, return to control levels occurred with MAGL, 2-AG, and AEA (48h) but not with ChE or [[FAAH]]. With the low dosage, return to control levels occurred with MAGL (12h), ChE and 2-AG (24h), and AEA (48h) but not with [[FAAH]]. With the lowest dosage, peak inhibition of [[FAAH]] (52%) is greater than that of ChE (24%) and that level of [[FAAH]] inhibition is sufficient to induce a persistent pattern of elevated AEA. It is possible that this pattern of elevation could alter the appropriate development of neuronal brain circuits. 
|mesh-terms=* Aging
* Amidohydrolases
* Animals
* Arachidonic Acids
* Brain
* Chlorpyrifos
* Cholinesterase Inhibitors
* Endocannabinoids
* Female
* Glycerides
* Insecticides
* Male
* Monoacylglycerol Lipases
* Polyunsaturated Alkamides
* Rats
* Rats, Sprague-Dawley
|keywords=* chlorpyrifos
* developmental
* neurotoxicity
* organophosphate.
* pesticides
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954109
}}
{{medline-entry
|title=The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/22537429
|abstract=Several factors contribute to the deterioration in synaptic plasticity which accompanies age and one of these is neuroinflammation. This is characterized by increased microglial activation associated with increased production of proinflammatory cytokines like interleukin-1β (IL-1β). In aged rats these neuroinflammatory changes are associated with a decreased ability of animals to sustain long-term potentiation (LTP) in the dentate gyrus. Importantly, treatment of aged rats with agents which possess anti-inflammatory properties to decrease microglial activation, improves LTP. It is known that endocannabinoids, such as anandamide (AEA), have anti-inflammatory properties and therefore have the potential to decrease the age-related microglial activation. However, endocannabinoids are extremely labile and are hydrolyzed quickly after production. Here we investigated the possibility that inhibiting the degradation of endocannabinoids with the fatty acid amide hydrolase ([[FAAH]]) inhibitor, URB597, could ameliorate age-related increases in microglial activation and the associated decrease in LTP. Young and aged rats received subcutaneous injections of the [[FAAH]] inhibitor URB597 every second day and controls which received subcutaneous injections of 30% DMSO-saline every second day for 28 days. Long-term potentiation was recorded on day 28 and the animals were sacrificed. Brain tissue was analyzed for markers of microglial activation by PCR and for levels of endocannabinoids by liquid chromatography coupled to tandem mass spectrometry. The data indicate that expression of markers of microglial activation, MHCII, and [[CD68]] mRNA, were increased in the hippocampus of aged, compared with young, rats and that these changes were associated with increased expression of the proinflammatory cytokines interleukin (IL)-1β and tumor necrosis factor-α (TNFα) which were attenuated by treatment with URB597. Coupled with these changes, we observed an age-related decrease in LTP in the dentate gyrus which was partially restored in URB597-treated aged rats. The data suggest that enhancement of levels of endocannabinoids in the brain by URB597 has beneficial effects on synaptic function, perhaps by modulating microglial activation.
|mesh-terms=* Aging
* Amidohydrolases
* Animals
* Anti-Inflammatory Agents, Non-Steroidal
* Benzamides
* Carbamates
* Hippocampus
* Long-Term Potentiation
* Male
* Microglia
* Rats
* Rats, Wistar

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409037
}}
{{medline-entry
|title=Effects of chronic bhang (cannabis) administration on the reproductive system of male mice.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/21678546
|abstract=The purpose of this study was to investigate the effect of chronic uptake of bhang, prepared from the Cannabis sativa, on male reproductive physiology in adult male Parkes strain (P) mice. An attempt was also made to investigate the presence of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors, and fatty acid amide hydrolase ([[FAAH]]) in the testis and to evaluate any changes in it resulting from chronic intake of bhang in mice. Adult male mice were given bhang (3 or 6 mg/kg body weight/day) orally for 36 consecutive days. Chronic intake of bhang caused regressive changes in the testes and suppressed sperm count, viability and motility. Bhang intake also caused significant decline in circulating testosterone level due to decline in testicular 3β HSD enzyme activity. An immunohistochemical study demonstrated the presence of CB1, CB2 and [[FAAH]] in the testis of mice. The present study also showed significant variation in the CB1 and CB2 receptors and [[FAAH]] protein levels in testes of mice exposed to bhang. These suppressive effects may be due to inhibitory effect of bhang on pituitary expression of gonadotrophin releasing hormone (GnRH) I receptor protein. Treatment of testes with bhang in vitro significantly decreased testicular luteinizing hormone receptor (LHR) and [[FAAH]] expression suggesting direct action of bhang on testicular activity. The findings of this study thus suggest that bhang may impair fertility in male mice through alteration in the testicular endocannabinoid system and that chronic bhang exposure in humans would be predicted to alter male fertility.
|mesh-terms=* Aging
* Alanine Transaminase
* Animals
* Apoptosis
* Aspartate Aminotransferases
* Body Weight
* Cannabis
* Cell Survival
* Fertility
* Genitalia, Male
* Immunohistochemistry
* Male
* Mice
* Organ Size
* Receptors, Cell Surface
* Sperm Count
* Sperm Motility
* Testis
* Testosterone

|full-text-url=https://sci-hub.do/10.1002/bdrb.20295
}}
{{medline-entry
|title=A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/18562209
|abstract=The subventricular zone (SVZ) is a major site of neurogenesis in the adult. We now show that ependymal and proliferating cells in the adult mouse SVZ express diacylglycerol lipases (DAGLs), enzymes that synthesise a CB1/CB2 cannabinoid receptor ligand. DAGL and CB2 antagonists inhibit the proliferation of cultured neural stem cells, and the proliferation of progenitor cells in young animals. Furthermore, CB2 agonists stimulate progenitor cell proliferation in vivo, with this effect being more pronounced in older animals. A similar response was seen with a fatty acid amide hydrolase ([[FAAH]]) inhibitor that limits degradation of endocannabinoids. The effects on proliferation were mirrored in changes in the number of neuroblasts migrating from the SVZ to the olfactory bulb (OB). In this context, CB2 antagonists reduced the number of newborn neurons appearing in the OB in the young adult animals while CB2 agonists stimulated this in older animals. These data identify CB2 receptor agonists and [[FAAH]] inhibitors as agents that can counteract the naturally observed decline in adult neurogenesis that is associated with ageing.
|mesh-terms=* Age Factors
* Aging
* Animals
* Cell Differentiation
* Cell Line
* Cells, Cultured
* Cerebral Ventricles
* Female
* Lipoprotein Lipase
* Mice
* Mice, Inbred C57BL
* Mice, Knockout
* Neurons
* Receptor, Cannabinoid, CB2
* Signal Transduction
* Stem Cells

|full-text-url=https://sci-hub.do/10.1016/j.mcn.2008.05.001
}}
{{medline-entry
|title=A human fatty acid amide hydrolase ([[FAAH]]) functional gene variant is associated with lower blood pressure in young males.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/18497731
|abstract=Fatty acid amide hydrolase ([[FAAH]]) inhibitors, preventing endocannabinoid (EC) degradation, reduce blood pressure (BP) and heart rate in young male (YM) hypertensive rodents. The functional human [[FAAH]] 129T gene variant results in reduced protein level and enzymatic activity but its relationship with BP is unknown. This study investigates the relationship among [[FAAH]] P129T alleles and cardiovascular features in YMs at baseline and after 9-year follow-up, and in older male obese hypertensive (OH) patients, in whom the EC system (ECS) is overactive. Genotype analysis was performed in 215 Caucasian male students (24 (0.2) years old) and in 185 older OH patients (50 (0.2) years old). YMs were also followed up for 9 years. Clinical and anthropometric variables, BP, cardiac and carotid artery echographic measurements were evaluated. YMs with the [[FAAH]] 129T allele had lower systolic (P = 0.042) and mean BP (P = 0.022), and a trend toward lower diastolic BP (P = 0.06). Such significant association was maintained at follow-up. In contrast, the same allele was not associated with BP in older OH. No association was found with other cardiac and vascular variables. An [[FAAH]] defective gene variant results in lower BP in YMs, similar to the findings in young rodents. This effect is lost in older OH patients. Because cannabinoid CB1 receptor blockade is associated with BP reduction in OH patients, EC effects and the use of ECS-interfering drugs is likely to be age and clinical-condition dependent.
|mesh-terms=* Adult
* Aging
* Amidohydrolases
* Blood Pressure
* Follow-Up Studies
* Genetic Variation
* Genotype
* Humans
* Hypertension
* Male
* Middle Aged
* Obesity
* Receptor, Cannabinoid, CB1

|full-text-url=https://sci-hub.do/10.1038/ajh.2008.198
}}
{{medline-entry
|title=Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/17434980
|abstract=Recent studies have uncovered important cross talk between inflammation, generation of reactive oxygen and nitrogen species, and lipid metabolism in the pathogenesis of cardiovascular aging. Inhibition of the endocannabinoid anandamide metabolizing enzyme, the fatty acid amide hydrolase ([[FAAH]]), is emerging as a promising novel approach for the treatment of various inflammatory disorders. In this study, we have investigated the age-associated decline of cardiac function and changes in inflammatory gene expression, nitrative stress, and apoptosis in [[FAAH]] knockout ([[FAAH]](-/-)) mice and their wild-type ([[FAAH]]( / )) littermates. Additionally, we have explored the effects of anandamide on [[TNF]]-alpha-induced ICAM-1 and VCAM-1 expression and monocyte-endothelial adhesion in human coronary artery endothelial cells (HCAECs). There was no difference in the cardiac function (measured by the pressure-volume conductance catheter system) between 2- to 3-mo-old (young) [[FAAH]](-/-) and [[FAAH]]( / ) mice. In contrast, the aging-associated decline in cardiac function and increased myocardial gene expression of [[TNF]]-alpha, gp91phox, matrix metalloproteinase (MMP)-2, MMP-9, caspase-3 and caspase-9, myocardial inducible nitric oxide synthase protein expression, nitrotyrosine formation, poly (ADP-ribose)polymerase cleavage and caspase-3/9 activity, observed in 28- to 31-mo-old (aging) [[FAAH]]( / ) mice, were largely attenuated in knockouts. There was no difference in the myocardial cannabinoid CB(1) and CB(2) receptor gene expression between young and aging [[FAAH]](-/-) and [[FAAH]]( / ) mice. Anandamide dose dependently attenuated the [[TNF]]-alpha-induced ICAM-1 and VCAM-1 expression, NF-kappaB activation in HCAECs, and the adhesion of monocytes to HCAECs in a CB(1)- and CB(2)-dependent manner. These findings suggest that pharmacological inhibition of [[FAAH]] may represent a novel protective strategy against chronic inflammation, oxidative/nitrative stress, and apoptosis associated with cardiovascular aging and atherosclerosis.
|mesh-terms=* Aging
* Amidohydrolases
* Animals
* Apoptosis
* Arachidonic Acids
* Cell Adhesion
* Cells, Cultured
* Coronary Vessels
* Endocannabinoids
* Endothelial Cells
* Gene Expression Regulation
* Humans
* Inflammation
* Intercellular Adhesion Molecule-1
* Mice
* Mice, Knockout
* Monocytes
* Myocardium
* NF-kappa B
* Polyunsaturated Alkamides
* Reactive Nitrogen Species
* Receptors, Cannabinoid
* Tumor Necrosis Factor-alpha
* Vascular Cell Adhesion Molecule-1
* Ventricular Dysfunction, Left

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225473
}}
{{medline-entry
|title=Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse Sertoli cells.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/12488326
|abstract=Anandamide (AEA), a prominent member of the endogenous ligands of cannabinoid receptors (endocannabinoids), is known to adversely affect female fertility. However, a potential role of AEA in male reproductive functions is unknown. Here we report evidence that immature mouse Sertoli cells have the biochemical tools to bind and inactivate AEA, i.e. a functional type-2 cannabinoid receptor (CB2R), a selective AEA membrane transporter, and an AEA-degrading enzyme fatty acid amide hydrolase. We show that, unlike CB2R, the activity of AEA membrane transporter and the activity and expression of [[FAAH]] decrease, whereas the apoptosis-inducing activity of AEA increases with age during the neonatal period. We also show that FSH reduces the apoptotic potential of AEA, but not that of its nonhydrolyzable analog methanandamide. Concomitantly, FSH enhances [[FAAH]] activity in a manner dependent on mRNA transcription and protein synthesis and apparently involving cAMP. These data demonstrate that Sertoli cells partake in the peripheral endocannabinoid system, and that FSH reduces the apoptotic potential of AEA by activating [[FAAH]]. Taken together, it can be suggested that the endocannabinoid network plays a role in the hormonal regulation of male fertility.
|mesh-terms=* Aging
* Amidohydrolases
* Aminoglutethimide
* Animal Population Groups
* Animals
* Apoptosis
* Arachidonic Acids
* Blotting, Western
* Brain Chemistry
* Cannabinoid Receptor Modulators
* Cell Membrane
* Cyclic AMP
* DNA Fragmentation
* Endocannabinoids
* Enzyme-Linked Immunosorbent Assay
* Fertility
* Follicle Stimulating Hormone
* Kinetics
* Male
* Mice
* Polyunsaturated Alkamides
* RNA, Messenger
* Receptors, Cannabinoid
* Receptors, Drug
* Reverse Transcriptase Polymerase Chain Reaction
* Sertoli Cells
* Tritium

|full-text-url=https://sci-hub.do/10.1210/en.2002-220544
}}
{{medline-entry
|title=Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/11982628
|abstract=Anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG) are the most active endocannabinoids at brain (CB1) cannabinoid receptors. CD1 mice lacking the CB1 receptors ("knockout" [KO] mutants) were compared with wildtype (WT) littermates for their ability to degrade AEA through an AEA membrane transporter ([[AMT]]) and an AEA hydrolase (fatty acid amide hydrolase, [[FAAH]]). The age dependence of [[AMT]] and [[FAAH]] activity were investigated in 1- or 4-month-old WT and KO animals, and found to increase with age in KO, but not WT, mice and to be higher in the hippocampus than in the cortex of all animals. AEA and 2-AG were detected in nmol/mg protein (microm) concentrations in both regions, though the hippocampus showed approximately twice the amount found in the cortex. In the same regions, 2-AG failed to change across groups, while AEA was significantly decreased (approximately 30%) in hippocampus, but not in cortex, of old KO mice, when compared with young KO or age-matched WT animals. In the open-field test under bright light and in the lit-dark exploration model of anxiety, young KO mice, compared with old KO, exhibited a mild anxiety-related behaviour. In contrast, neither the increase in memory performance assessed by the object recognition test, nor the reduction of morphine withdrawal symptoms, showed age dependence in CB1 KO mice. These results suggest that invalidation of the CB1 receptor gene is associated with age-dependent adaptive changes of endocannabinoid metabolism which appear to correlate with the waning of the anxiety-like behaviour exhibited by young CB1 KO mice.
|mesh-terms=* Adaptation, Physiological
* Aging
* Amidohydrolases
* Animals
* Arachidonic Acids
* Behavior, Animal
* Brain
* Brain Chemistry
* Cannabinoid Receptor Modulators
* Carrier Proteins
* Cerebral Cortex
* Down-Regulation
* Endocannabinoids
* Hippocampus
* Mice
* Mice, Knockout
* Neurons
* Pain
* Pain Threshold
* Polyunsaturated Alkamides
* Receptors, Cannabinoid
* Receptors, Drug
* Recognition, Psychology
* Substance Withdrawal Syndrome
* Synaptosomes

|full-text-url=https://sci-hub.do/10.1046/j.1460-9568.2002.01957.x
}}
{{medline-entry
|title=Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/11461969
|abstract=CD1 mice lacking the CB1 receptors (knockout, KO) were compared with wild-type littermates for their ability to degrade N-arachidonoylethanolamine (anandamide, AEA) through a membrane transporter ([[AMT]]) and a fatty acid amide hydrolase ([[FAAH]]). The regional distribution and age-dependence of [[AMT]] and [[FAAH]] activity were investigated. Anandamide membrane transporter and [[FAAH]] increased with age in knockout mice, whereas they showed minor changes in wild-type animals. Remarkably, they were higher in all brain areas of 6-month-old knockout versus wild-type mice, and even higher in 12-month-old animals. The molecular mass (approximately 67 kDa) and isoelectric point (approximately 7.6) of mouse brain [[FAAH]] were determined and the [[FAAH]] protein content was shown to parallel the enzyme activity. The kinetic constants of [[AMT]] and [[FAAH]] in the cortex of wild-type and knockout mice at different ages suggested that different amounts of the same proteins were expressed. The cortex and hippocampus of wild-type and knockout mice contained the following N-acylethanolamines: AEA (8% of total), 2-arachidonoylglycerol (5%), N-oleoylethanolamine (20%), N-palmitoylethanolamine (53%) and N-stearoylethanolamine (14%). These compounds were twice as abundant in the hippocampus as in the cortex. Minor differences were observed in AEA or 2-arachidonoylglycerol content in knockout versus wild-type mice, whereas the other compounds were lower in the hippocampus of knockout versus wild-type animals.
|mesh-terms=* Aging
* Amidohydrolases
* Animals
* Arachidonic Acids
* Biological Transport
* Brain
* Cannabinoids
* Carrier Proteins
* Cell Membrane
* Cerebellum
* Cerebral Cortex
* Corpus Striatum
* Endocannabinoids
* Ethanolamines
* Glycerides
* Hippocampus
* Kinetics
* Mice
* Mice, Knockout
* Neurotransmitter Agents
* Organ Specificity
* Polyunsaturated Alkamides
* Receptors, Cannabinoid
* Receptors, Drug
* Synaptosomes

|full-text-url=https://sci-hub.do/10.1046/j.1471-4159.2001.00413.x
}}